Joshua Searle

Joshua Searle

Auto-generated profile, based on publicly available information

Joshua Searle

Cell Signalling Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester, UK.

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2025 in Molecular Cancer Research
Verified
Journal Article
Closed access
Martin J BakerMartin J Baker
Martin J Baker
SZSuli Zhang
Suli Zhang
DZDaniel Zhang
Daniel Zhang
JSJoshua Searle
Joshua Searle
PLPriti Lal
Priti Lal
MCMariana Cooke
Mariana Cooke
The small G-protein Rac1 is a central player in cancer progression and metastatic dissemination. Rac1 has been established as a bona fide effector of receptor tyrosine kinases, acting as a signaling node for motility, invasiveness, mitogenesis, and gene expression. Previous studies demonstrated that Rac1 is hyperactivated in aggressive cellular models of prostate cancer. In this study, we demonstrate that CRISPR/Cas9-mediated knockout of Rac1 results in impaired proliferation and migration of prostate cancer cells. Rac1-null cells display profound alterations in transcriptional programs, particularly those associated with cell adhesion and extracellular matrix regulation. Combined expression profiling and unbiased RNAi screening of Rac1 guanine nucleotide exchange factors identified VAV2 as the foremost mediator EGF-induced GTP loading onto Rac1 in prostate cancer cells. Depletion of VAV2 from prostate cancer cells significantly reduced their proliferative and migratory capacities without affecting the expression of Rac1-regulated genes, suggesting that VAV2 controls a discrete subset of Rac1-dependent cellular responses. IHC assessment in human prostate biopsies showed significant VAV2 overexpression in tumor areas. Bioinformatic analysis revealed a strong correlation between VAV2 expression and poor clinical prognosis. In addition to uncovering a prominent role for VAV2–Rac1 as an effector pathway mediating EGFR-driven proliferative and migratory responses in prostate cancer cells, our findings underscore the potential prognostic value of VAV2 in human prostate cancer progression. Implications: This study highlights the central role of VAV2 in prostate cancer cell proliferation and migration, as well as its potential prognostic value in disease progression.

22 June 2026 in Cancer Discovery
Verified
Journal Article
Open access
WMWilliam J. McDaid
William J. McDaid
HAHelen Adderley
Helen Adderley
PDPaolo Davide D’Arienzo
Paolo Davide D’Arienzo
APAna Sofia de Freitas Matos Parreira
Ana Sofia de Freitas Matos Parreira
LWLaura C. Woodhouse
Laura C. Woodhouse
CLColin R. Lindsay
Colin R. Lindsay
Direct inhibitors of KRASG12C are now used as standard-of-care therapy in KRASG12C-mutant non–small cell lung cancer (NSCLC), but less is understood about the molecular mechanisms and consequent treatment vulnerabilities of KRAS codon 13 mutations in this setting. In this study, we characterized the tumorigenic properties of NSCLC harboring KRASG13X in a large multinational cohort of patients with NSCLC and in preclinical models of KRASG13X NSCLC. Induction of KRASG13C or KRASG13D expression confers reduced oncopotency compared with allele-specific controls affecting KRAS codon 12, particularly KRASG13C. We identified functionally relevant comutations in KRASG13X NSCLC, including KEAP1, STK11, BRAF, and NF1. The novel RAS(ON) G13C-selective inhibitor, RMC-8839, reduces viability in a panel of KRASG13C NSCLC cell models. To determine combination partners that enhance RAS(ON) mutant-selective inhibition, a drug repurposing screen revealed that KRASG13C models are selectively vulnerable to chemotherapy. Combination of docetaxel with RMC-8839 demonstrated robust antiproliferative activity in KRASG13C-driven NSCLC models in vitro and in vivo. Significance: We characterize the second most common KRAS mutational hotspot in NSCLC after codon 12, KRASG13X, from tumor initiation to advanced disease. KRASG13C is a novel, directly targetable subset of NSCLC, with vulnerability to the combination of chemotherapeutics and the mutant-selective RAS(ON) inhibitor RMC-8839, a finding immediately relevant to patient care. See related commentary by Araujo and Skoulidi, p. 2206 See related article by Seamon et al., p. 2256

2 November 2026
Verified
Other
Open access
WMWilliam J. McDaid
William J. McDaid
HAHelen Adderley
Helen Adderley
PDPaolo Davide D’Arienzo
Paolo Davide D’Arienzo
APAna Sofia de Freitas Matos Parreira
Ana Sofia de Freitas Matos Parreira
LWLaura C. Woodhouse
Laura C. Woodhouse
CLColin R. Lindsay
Colin R. Lindsay
Examining the response and molecular determinants of PD-1 immune checkpoint blockade in KRASG13X NSCLC. A, Schematic illustrating the use of RAS-PM to explore ICI-specific outcomes, TMB, and PD-L1 in patients affected by advanced/inoperable KRAS-mutant NSCLC. B, Percentage of patients within the codon 13 cohort harboring KRASG13C, KRASG13D, and other codon 13 mutations. C, Analysis of TMB between KRASG12C and KRASG13C patients and between KRASG12D and KRASG13D patients from cBioPortal. D, PFS between KRAS codon 12 and 13 mutant NSCLC patients receiving immunotherapy as first-line treatment. E, OS between KRAS codon 12 and 13 mutant NSCLC patients receiving immunotherapy first-line treatment. F, The percentage of comutations associated with KRASG12C-, KRASG12D-, KRASG13C-, and KRASG13D-mutant patients taken from the 100,000 Genomes Project. Comparisons are as follows: KRASG12X (n = 155) vs. KRASG13X (n = 26), KRASG12C (n = 115) vs. KRASG13C (n = 14), and KRASG12D (n = 40) vs. KRASG13D (n = 12). G, The percentage of comutations associated with KRASG12C-, KRASG12D-, KRASG13C-, and KRASG13D-mutant patients taken from RAS-PM. Comparisons are as follows: KRASG12X vs. KRASG13X, KRASG12C vs. KRASG13C, and KRASG12D vs. KRASG13D. Not every patient was tested for all 5 comutations simultaneously. Refer to Supplementary Table S3 for the numbers of patients tested for each comutation. H, Schematic illustrating factors contributing to the lack of difference in immunotherapy response between KRASG12X- and KRASG13X-driven NSCLC patients from the RAS-PM database. Statistical significance between comparisons was calculated using an unpaired Student t test (C), log-rank (Mantel–Cox; D and E), and Fisher exact test (F and G). ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns > 0.05. A, Created in BioRender. Tinsley, K. (2026) https://BioRender.com/vyu8cs2; H, Created in BioRender. Tinsley, K. (2026) https://BioRender.com/4ju5v3u.

2 November 2026
Verified
Other
Open access
WMWilliam J. McDaid
William J. McDaid
HAHelen Adderley
Helen Adderley
PDPaolo Davide D’Arienzo
Paolo Davide D’Arienzo
APAna Sofia de Freitas Matos Parreira
Ana Sofia de Freitas Matos Parreira
LWLaura C. Woodhouse
Laura C. Woodhouse
CLColin R. Lindsay
Colin R. Lindsay
Selective sensitivity of KRASG13C NSCLC to chemotherapy. A, Top 25 compounds demonstrating the highest sensitivity to KRASG13C-driven NSCLC cell lines compared with cell lines with other KRAS-mutant genotypes. Each dot represents a cell line and is the mean of two repeats. The dashed line indicates the midway point between the most resistant and the most sensitive cell line for every compound, with cell lines to the left of the dashed line deemed drug-sensitive and cell lines to the right deemed drug-resistant. Each cell line is considered a genotype-specific biological replicate: KRASG12C (blue), n = 4 cell lines; KRASG12D (red), n = 3 cell lines; KRASG13C (green), n = 2 cell lines; and KRASG13D (purple), n = 4 cell lines. The dot represents the mean of the technical duplicate. Black arrows indicate compounds of interest. B, 2D (left) and 3D (right) viability of advanced cancer cell lines expressing either KRASG12C (H358, H23, HCC1171, H2030, H1792, and HOP62), KRASG12D (SKLU-1, A427, and HCC461), KRASG13C (H1734, H1355, HCC4087, and MOR), or KRASG13D (H647, H1944, HCC515, and HCC1974) exposed to 1 μmol/L docetaxel, 1 μmol/L paclitaxel, 1 μmol/L vincristine, 1 μmol/L epirubicin, 1 μmol/L gemcitabine, and 100 μmol/L carboplatin. Viability was measured by CellTiter-Glo (3D) 72 hours later. Data are expressed as a percentage of DMSO control. n = 3 per cell line with the mean of three biological repeats shown as a dot. Error bars represent mean ± SEM of all cell lines within each condition (KRASG12C + KRASG12D + KRASG13D vs. KRASG13C). Two KRASG12C lines (H2030 and HCC1171) were excluded from vincristine response in 3D analysis due to a viability increase of more than 180% relative to DMSO control. C, PFS between patients with KRASG13C and those with KRASG12C, KRASG12D, KRASG12V, or KRASG13D NSCLC receiving first-line chemotherapy. Data are taken from the Francophone de Cancérologie Thoracique dataset (51). D, Dose-response analysis of isogenic MLE-12 cells previously treated with DOX for 24 hours to induce KRAS variant expression in 0.5% serum, followed by a 72-hour treatment with a concentration range of indicated chemotherapeutics. Cells were plated in ULA conditions. Viability was analyzed by CellTiter-Glo 3D. Data are expressed as a percentage of DMSO control. n = 3 biological repeats per isogenic cell line; mean ± SEM. IC values were calculated for each cell line and presented as a table. E, Apoptosis quantification of all cell lines used in B (except H1792) after 72 hours of exposure to either 100 nmol/L docetaxel or 100 nmol/L paclitaxel. Cells were stained with FITC-conjugated annexin V to detect apoptotic cells. n = 3 biological repeats per cell line with the mean of three biological repeats shown as a dot. Error bars represent mean ± SEM of all cell lines within each condition. F, Viability of advanced cancer cell lines expressing (left) KRASG13C and (right) KRASG12C, KRASG12D, and KRASG13D grouped together, exposed to 1 μmol/L vincristine or either 100 or 1,000 nmol/L navitoclax or both compounds in combination. Viability was measured by CellTiter-Glo (3D) 72 hours later. Data are expressed as a percentage of DMSO control. n = 3 per cell line with the mean of 2 or 3 biological repeats shown as a dot. Error bars represent mean ± SEM of all cell lines within each condition. G, Viability of advanced cancer cell lines expressing (left) KRASG13C and (right) KRASG12C, KRASG12D, and KRASG13D grouped together exposed to 1 μmol/L epirubicin or either 100 or 1,000 nmol/L navitoclax or both compounds in combination. Viability was measured by CellTiter-Glo (3D) 72 hours later. Data are expressed as a percentage of DMSO control. n = 3 per cell line with the mean of 2 or 3 biological repeats shown as a dot. Error bars represent mean ± SEM of all cell lines within each condition. Statistical significance between comparisons was calculated using an unpaired Student t test (B), log-rank (Mantel–Cox; C), a two-way ANOVA (E), and a one-way ANOVA (F and G). COMB, combination. ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns > 0.05.

2 November 2026
Verified
Other
Open access
WMWilliam J. McDaid
William J. McDaid
HAHelen Adderley
Helen Adderley
PDPaolo Davide D’Arienzo
Paolo Davide D’Arienzo
APAna Sofia de Freitas Matos Parreira
Ana Sofia de Freitas Matos Parreira
LWLaura C. Woodhouse
Laura C. Woodhouse
CLColin R. Lindsay
Colin R. Lindsay
Examining a novel RAS(ON)-G13C selective inhibitor, RMC-8839. A, Western blotting of isogenic MLE-12 cells previously treated with DOX for 24 hours to induce KRAS variant expression in 0.5% serum followed by 6 hours of treatment with 50 nmol/L RMC-7977. Cells were plated in ULA conditions. Data are representative of three biological repeats. Vinculin was used as a protein loading control. B, Quantification of pERK 1/2 from A. Phosphorylated ERK 1/2 and total ERK 1/2 run on separate blots were normalized to their respective loading controls on the same blot, and then pERK 1/2 was normalized to total ERK 1/2. The data for each isogenic line were then normalized to the DMSO control of that line. n = 3 biological repeats per isogenic cell line; mean ± SEM. C, Dose-response analysis of isogenic MLE-12 cells previously treated with DOX for 24 hours to induce KRAS variant expression in 0.5% serum, followed by 72 hours of treatment with a concentration range of RMC-7977. Cells were plated in ULA conditions. Viability was analyzed by CellTiter-Glo 3D. Data are expressed as a % of DMSO control. n = 3 biological repeats per isogenic cell line; mean ± SEM. IC50 values were calculated for each cell line and presented as a table. D, Western blotting of isogenic MLE-12 cells previously treated with DOX for 24 hours to induce KRAS variant expression in 0.5% serum, followed by 6 hours of treatment with 50 nmol/L RMC-8839. Cells were plated in ULA conditions. Data are representative of three biological repeats. Vinculin was used as a protein loading control. E, Quantification of pERK 1/2 from D. Phosphorylated ERK 1/2 and total ERK 1/2 run on separate blots were normalized to their respective loading controls on the same blot, and then pERK 1/2 was normalized to total ERK 1/2. The data for each isogenic line were then normalized to the DMSO control of that line. n = 3 biological repeats per isogenic cell line; mean ± SEM. F, Dose-response analysis of isogenic MLE-12 cells previously treated with DOX for 24 hours to induce KRAS variant expression in 0.5% serum followed by a 72-hour treatment with a concentration range of RMC-8839. Cells were plated in ULA conditions. Viability was analyzed by CellTiter-Glo 3D. Data are expressed as a percentage of DMSO control. n = 3 biological replicates per isogenic cell line; mean ± SEM. IC50 values were calculated for each cell line and presented as a table. G, Viability in response to 10 nmol/L RMC-7977 in advanced KRAS-mutant NSCLC cell lines grouped by KRAS codon genotype. Cells were plated in ULA conditions. Viability was analyzed after 72 hours by CellTiter-Glo 3D. Each dot represents a cell line within that genotype. Data are expressed as a percentage of DMSO control. n = 3 biological repeats per cell line; mean ± SEM. H, Western blotting of KRASG13C advanced cancer cell lines 24 hours after exposure to 100 nmol/L RMC-8839. Cells were plated in ULA conditions. Data are representative of three biological repeats per cell line. Vinculin was used as a protein loading control. I, Dose response analysis of advanced cancer cell lines harboring KRASG13C (H1734, H1355, HCC4087, and MOR), KRASG12C (H2030), KRASG12D (SKLU-1), and KRASG13D (H647) exposed to increasing concentrations of RMC-8839 for 168 hours. Viability was measured by CellTiter-Glo 3D. Data are expressed as a percentage of DMSO control. n = 3–4 biological repeats per cell line; mean ± SEM. IC50 values were calculated for each cell line and presented as a table. J, Apoptosis detection (left) and quantification (right) of H1734, MOR, HCC4087, and H1355 cells after 120 hours of exposure to 100 nmol/L RMC-8839. Cells were stained with annexin V and propidium iodide to detect apoptotic cells. n = 3 biological repeats per cell line; mean ± SEM. Statistical significance between comparisons was calculated using an unpaired Student t test (B, E, and G) and a two-way ANOVA (J). ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns > 0.05.

2 November 2026
Verified
Other
Open access
WMWilliam J. McDaid
William J. McDaid
HAHelen Adderley
Helen Adderley
PDPaolo Davide D’Arienzo
Paolo Davide D’Arienzo
APAna Sofia de Freitas Matos Parreira
Ana Sofia de Freitas Matos Parreira
LWLaura C. Woodhouse
Laura C. Woodhouse
CLColin R. Lindsay
Colin R. Lindsay
KRAS codon 13 mutations confer reduced oncopotency. A, Schematic outlining the generation of DOX-inducible isogenic MLE-12 and BEAS-2B cells to compare the effect of expressing different mutant KRAS variants on NSCLC initiation. B, Relative viability of isogenic MLE-12 cells 96 hours after DOX-induced expression (100 ng/mL) of each mutant KRAS variant in three different serum conditions – 2%, 0.5%, and 0.1% FBS. Cells were plated in ULA conditions. Viability was analyzed using CellTiter-Glo 3D. Data for each isogenic line are expressed relative to the untreated (no DOX) control of that particular line. n = 3 biological repeats; mean ± SEM. C, Western blotting of isogenic MLE-12 cells 24 hours after DOX-induced expression (100 ng/mL) of each mutant KRAS variant in 0.5% serum. Cells were plated in ULA conditions. Data are representative of five biological repeats for KRAS effector proteins and four biological repeats for KRAS target proteins. Dashed lines indicate that representative blots from three different biological replicates are presented. Vinculin and α-tubulin were used as protein loading controls. D, Quantification of C and associated replicates. For phospho-proteins (KRAS effector blots), phosphorylated protein and total protein run on separate blots were normalized to their respective loading controls on the same blot, and then phospho-protein was normalized to the total protein. Data for each isogenic line were then normalized to the untreated (no DOX) control of that particular line. KRAS target proteins were normalized to the loading control, and then the data were normalized to the untreated (no DOX) control. n = 5 biological repeats for KRAS effector proteins and four biological repeats for KRAS target proteins; mean ± SEM. E, (Left) Timeline of BEAS-2B oncogenicity in vivo experiment using chicken egg xenograft. (Right) Normalized tumor weights measured upon termination of the experiment. Number of eggs indicated per condition. Mean ± SEM reported. Statistical significance between comparisons was calculated using a two-way ANOVA (B, D, and E). ****, P < 0.0001; ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, > 0.05. A, Created in BioRender. Tinsley, K. (2026) https://BioRender.com/ojsukx1; E, (Left) Created in BioRender. Tinsley, K. (2026) https://BioRender.com/wrfehon.